Table 3.
The study outcomes in patients randomized to placebo or rHuEPO group
| Placebo group (n = 50) | rHuEPO group (n = 50) | p value | |
|---|---|---|---|
|
Incidence of AKI n (%) |
19 (38) |
7 (14) |
<0.01 |
| eGFR > 60 mL/min/1.73 m2 |
6/24 (25) |
1/19 (5.26) |
0.11 |
| eGFR < 60 mL/min/1.73 m2 |
13/26 (50) |
6/31 (19.35) |
<0.05 |
|
Postoperative complication: |
|
||
| Bleeding n (%) |
2 (4) |
1 (2) |
0.56 |
| Infection n (%) |
4 (8) |
2 (4) |
0.41 |
| Stroke n (%) |
1 (2) |
0 (0) |
0.32 |
| Cardiac arrhythmia n (%) |
7 (14) |
6 (12) |
0.77 |
| Myocardial infarction n (%) |
1 (2) |
0 (0) |
0.32 |
| Hemodialysis n (%) |
2 (4) |
0 (0) |
0.16 |
|
Hospital stay and mortality |
|
||
| ICU stay (days) |
7 ± 4 |
4 ± 1 |
<0.01 |
| Hospital stay (days) |
17 ± 9 |
11 ± 2 |
<0.01 |
| Hospital deaths n (%) | 2 (4) | 0 (0) | 0.16 |
eGFR indicates estimated glomerular filtration rate.
ICU indicates intensive care unit.